Gap‍

Critical need for more and better PTSD treatment options PTSD costs society billions in health care & lost productivity

Rationale‍

Address a long felt need for a treatment & ROA designed for the psychiatrist’s office Develop an indication that expands beyond TRD, which is becoming crowded with empathogens & 5HT2A agonists

Market Opportunity‍

$2.3B global¹

‍

¹ Coherent Market Research

Gap

DMT is the prototypical psychedelic but:

• Inhaled is too fast and strong. 
• IV delivery is expensive, & psychiatrists don’t offer IVs
• Oral dosing requires dangerous MAO inhibitors

Rationale

DMT shows strong potential in mental health if you can control entry, altitude and exit of the experience. Bexson's Sub-Q DMT + pump can manage this gracefully.

Market Opportunity

$1.2B global¹

‍

¹ Coherent Market Research

Gap

IV-only infusion treatments are very expensive.⁴ Requires in-clinic IV administration or very expensive at home services.

Rationale

Moving from IV to SubQ wearable delivery will improve patient safety & convenience. Large cost savings by removing clinic and daily IV services. 505b2 regulatory pathway

Market Opportunity

>$1.5B U.S.⁵

‍

‍

⁴ JAMA Network Open. 2022
⁵ Research and Markets (Dec 2021)

‍Problem

Decriminalization efforts have obscured awareness of the need for diversion control for scheduled drugs for FDA approval.

‍

Solution

Bexson’s wearable system is specifically designed with layered protections against drug diversion and tampering.

‍Problem

Psychiatrists do not offer IV service. IV drug delivery is expensive, medicalized & uncomfortable.

‍

Solution

Drug delivery by a wearable, pre-programmed device reduces cost and is much more patient friendly. Matches the cultural and practical realities of the target specialty - PSYCHIATRY.

‍

‍Problem

Oral dosing sends medicine through the GI tract, which is laden with 5HT2A receptors, causing nausea, vomiting and malaise with psychedelics.

‍

Solution

SubQ administration skips the GI tract to substantially reduce side effects, and improve psychic aspects of the treatment.

‍Problem

Oral dosing sends drug by the liver creating large variations in blood level and response. Correct therapeutic effect should not be so hard to achieve.

‍

Solution

SubQ delivery avoids the GI tract and early drug metabolism, instead going through SubQ tissue into the bloodstream.

‍Problem

Waiting for onset and multiple hour timeframes with oral dosing is not a viable model in many cases

‍

Solution

Bexson’s Subcutaneous formulations & wearable device offer full control of ONSET, ALTITUDE & LANDING of a treatment. Wearable subQ infusion can be thought of as a pocket IV.

‍